ORIC PHARMACEUTICALS INC (ORIC) Fundamental Analysis & Valuation

NASDAQ:ORIC • US68622P1093

Current stock price

9.605 USD
+0.17 (+1.75%)
Last:

This ORIC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ORIC Profitability Analysis

1.1 Basic Checks

  • In the past year ORIC has reported negative net income.
  • ORIC had a negative operating cash flow in the past year.
  • ORIC had negative earnings in each of the past 5 years.
  • ORIC had a negative operating cash flow in each of the past 5 years.
ORIC Yearly Net Income VS EBIT VS OCF VS FCFORIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • ORIC has a Return On Assets of -31.66%. This is in the better half of the industry: ORIC outperforms 62.14% of its industry peers.
  • With a decent Return On Equity value of -33.68%, ORIC is doing good in the industry, outperforming 72.23% of the companies in the same industry.
Industry RankSector Rank
ROA -31.66%
ROE -33.68%
ROIC N/A
ROA(3y)-39.42%
ROA(5y)-36.13%
ROE(3y)-43.74%
ROE(5y)-40.02%
ROIC(3y)N/A
ROIC(5y)N/A
ORIC Yearly ROA, ROE, ROICORIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ORIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORIC Yearly Profit, Operating, Gross MarginsORIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ORIC Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ORIC has more shares outstanding
  • Compared to 5 years ago, ORIC has more shares outstanding
  • There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORIC Yearly Shares OutstandingORIC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
ORIC Yearly Total Debt VS Total AssetsORIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 20.44 indicates that ORIC is not in any danger for bankruptcy at the moment.
  • ORIC has a Altman-Z score of 20.44. This is amongst the best in the industry. ORIC outperforms 88.35% of its industry peers.
  • There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.44
ROIC/WACCN/A
WACCN/A
ORIC Yearly LT Debt VS Equity VS FCFORIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 14.13 indicates that ORIC has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 14.13, ORIC belongs to the top of the industry, outperforming 89.32% of the companies in the same industry.
  • A Quick Ratio of 14.13 indicates that ORIC has no problem at all paying its short term obligations.
  • ORIC has a better Quick ratio (14.13) than 89.32% of its industry peers.
Industry RankSector Rank
Current Ratio 14.13
Quick Ratio 14.13
ORIC Yearly Current Assets VS Current LiabilitesORIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ORIC Growth Analysis

3.1 Past

  • ORIC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.48%, which is quite good.
EPS 1Y (TTM)16.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 11.86% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.42%
EPS Next 2Y-2.04%
EPS Next 3Y-4.45%
EPS Next 5Y11.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORIC Yearly Revenue VS EstimatesORIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ORIC Yearly EPS VS EstimatesORIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ORIC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ORIC. In the last year negative earnings were reported.
  • Also next year ORIC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORIC Price Earnings VS Forward Price EarningsORIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORIC Per share dataORIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as ORIC's earnings are expected to decrease with -4.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.04%
EPS Next 3Y-4.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ORIC Dividend Analysis

5.1 Amount

  • ORIC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORIC Fundamentals: All Metrics, Ratios and Statistics

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (4/30/2026, 1:49:05 PM)

9.605

+0.17 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)02-23
Earnings (Next)05-11
Inst Owners113.29%
Inst Owner Change0.03%
Ins Owners1.27%
Ins Owner Change0.92%
Market Cap963.96M
Revenue(TTM)N/A
Net Income(TTM)-129.47M
Analysts86.67
Price Target21.42 (123.01%)
Short Float %23.03%
Short Ratio10.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.65%
Min EPS beat(2)19.17%
Max EPS beat(2)20.13%
EPS beat(4)3
Avg EPS beat(4)13.68%
Min EPS beat(4)-4.01%
Max EPS beat(4)20.13%
EPS beat(8)5
Avg EPS beat(8)8.14%
EPS beat(12)9
Avg EPS beat(12)7.56%
EPS beat(16)11
Avg EPS beat(16)6.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.52%
EPS NQ rev (3m)13.92%
EPS NY rev (1m)1.19%
EPS NY rev (3m)10.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS3.83
TBVpS3.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -31.66%
ROE -33.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.42%
ROA(5y)-36.13%
ROE(3y)-43.74%
ROE(5y)-40.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.13
Quick Ratio 14.13
Altman-Z 20.44
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)82.65%
Cap/Depr(5y)113.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
EPS Next Y5.42%
EPS Next 2Y-2.04%
EPS Next 3Y-4.45%
EPS Next 5Y11.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.06%
EBIT Next 3Y-5.9%
EBIT Next 5YN/A
FCF growth 1Y1.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.5%
OCF growth 3YN/A
OCF growth 5YN/A

ORIC PHARMACEUTICALS INC / ORIC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ORIC PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ORIC.


Can you provide the valuation status for ORIC PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ORIC PHARMACEUTICALS INC (ORIC). This can be considered as Overvalued.


Can you provide the profitability details for ORIC PHARMACEUTICALS INC?

ORIC PHARMACEUTICALS INC (ORIC) has a profitability rating of 1 / 10.


How financially healthy is ORIC PHARMACEUTICALS INC?

The financial health rating of ORIC PHARMACEUTICALS INC (ORIC) is 8 / 10.